45 results found.

Prostate Cancer Clinical Trial using Abiraterone Acetate; Prednisone 5 mg twice daily; Prednisone 5 mg once daily; Prednisone 2.5 mg twice daily; Dexamethasone 0.5 mg once daily

Janssen Pharmaceutica N.V., Belgium - Recruiting 18 years or older.
- A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-naïve and Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients.
Abiraterone Acetate; Prednisone 5 mg twice daily; Prednisone 5 mg once daily; Prednisone 2.5 mg twice daily; Dexamethasone 0.5 mg once daily

Prostate Cancer, Castration Resistant Prostate Cancer, Pain, or P Clinical Trial using cabozantinib; mitoxantrone; prednisone

Exelixis - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer.
cabozantinib; mitoxantrone; prednisone

Prostate Cancer, or Metastatic (Spread to Other Areas of the Body Clinical Trial using BKM120

Duke University - Recruiting 18 years or older.
- Phase II Study of BKM120 in Men With Metastatic Castration-Resistant Prostate Cancer.
BKM120

Prostate Cancer Clinical Trial using tasquinimod; tasquinimod 0.25 mg; 0.5 mg; tasquinimod 0.25 mg; 0.5 mg; 1.0 mg

Duke University - Recruiting 18 years to 79 years.
- The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Castration-Resistant Heavily Pre-treated Prostate Cancer.
tasquinimod; tasquinimod 0.25 mg; 0.5 mg; tasquinimod 0.25 mg; 0.5 mg; 1.0 mg

Prostatic Neoplasms Clinical Trial using BAY2010112

Bayer - Recruiting 18 years or older.
- An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY2010112 Given Once Daily by Subcutaneous Administration in Subjects With Castration-resistant Prostate Cancer.
BAY2010112

Prostate Cancer Clinical Trial using GDC-0068; GDC-0980; placebo; abiraterone; prednisone

Genentech - Recruiting 18 years or older.
- A Phase Ib/II Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy.
GDC-0068; GDC-0980; placebo; abiraterone; prednisone

Prostatic Neoplasms Clinical Trial using Radium-223 dichloride (Xofigo, BAY88-8223)

Bayer - Recruiting 18 years or older.
- A Re-treatment Safety Study of Radium-223 Dichloride in Subjects With Castration-resistant Prostate Cancer With Bone Metastases Who Received an Initial Course of Six Doses of Radium-223 Dichloride 50 kBq/kg Every Four Weeks.
Radium-223 dichloride (Xofigo, BAY88-8223)

Prostatic Neoplasms Clinical Trial using Radium-223 dichloride (Xofigo, BAY88-8223)

Bayer - Recruiting 18 years or older.
- A Single-arm, International, Prospective, Interventional, Open-label, Multicenter Study of Radium-223 Dichloride in the Treatment of Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastasis.
Radium-223 dichloride (Xofigo, BAY88-8223)

Castration-resistant Prostate Cancer Clinical Trial using BEZ235; BKM120

Novartis - Recruiting 18 years or older.
- Phase Ib Dose Finding Study of Abiraterone Acetate Plus BEZ235 or BKM120 in Patients With Castration-resistant Prostate Cancer..
BEZ235; BKM120

Prostate Cancer Metastatic Clinical Trial using CABAZITAXEL (XRP6258); DOCETAXEL (XRP6976); prednisone

Sanofi - Recruiting 18 years or older.
- Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy.
CABAZITAXEL (XRP6258); DOCETAXEL (XRP6976); prednisone

Prostatic Neoplasms Clinical Trial using Radium-223 dichloride (Xofigo, BAY88-8223)

Bayer - Recruiting 20 years or older.
- A Single-arm, Open-label, Multicenter, Phase II Study of BAY88-8223 in the Treatment of Japanese Patients With Symptomatic Castration-resistant Prostate Cancer (CRPC) With Bone Metastases.
Radium-223 dichloride (Xofigo, BAY88-8223)

Prostate Cancer, Metastatic Prostate Cancer, or Castration-resist Clinical Trial

Astellas Pharma Inc - Recruiting N/A or older.
- A Prospective, Longitudinal, Multinational, Observational Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk for Poor Clinical Outcomes After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-Resistant Prostate Cancer and Men With Metastatic Prostate Cancer at Initial Diagnosis.

Prostatic Neoplasms Clinical Trial using Radium-223 dichloride (BAY88-8223)

Bayer - Recruiting 18 years or older.
- Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases.
Radium-223 dichloride (BAY88-8223)

Prostatic Neoplams, Prostate Cancer, Neoplasm, Prostate, or Neopl Clinical Trial using AMG 386; Abiraterone; Prednisone

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer.
AMG 386; Abiraterone; Prednisone

Metastatic Castration-resistant Prostate Cancer, or Metastatic Br Clinical Trial using Abiraterone acetate

Janssen Research & Development, LLC - Recruiting N/A or older.
- A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study.
Abiraterone acetate

Prostate Cancer Clinical Trial using PROSTVAC-F/TRICOM; PROSTVAC-V/TRICOM; Enzalutamide (Xtandi)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men With Metastatic Castration Resistant Prostate Cancer.
PROSTVAC-F/TRICOM; PROSTVAC-V/TRICOM; Enzalutamide (Xtandi)

Prostate Cancer Clinical Trial using DSTP3086S

Genentech - Recruiting 18 years or older.
- A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer.
DSTP3086S

Castration-resistant Prostate Cancer Clinical Trial using F-Choline-PET

University Hospital, Grenoble - Recruiting 18 years or older.
- F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer Treated by Abiraterone Acetate or Enzalutamide.
F-Choline-PET

Prostate Cancer Clinical Trial using PSMA ADC

Progenics Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 2, Open-label, Multicenter Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer.
PSMA ADC

Prostate Cancer, or Prostatic Neoplasms Clinical Trial using Panobinostat; Bicalutamide

New York University School of Medicine - Recruiting 18 years or older.
- Phase I/II Randomized Trial of LBH589 (Panobinostat) at Two Dose Levels Combined With Bicalutamide (Casodex) in Men With Castration-resistant Prostate Cancer.
Panobinostat; Bicalutamide

Prostate Neoplasms, or Prostate Cancer Clinical Trial using Cohort 4; Cohort 3; Cohort 2; Cohort 1

Cougar Biotechnology, Inc. - Recruiting 18 years or older.
- A Phase 1b Safety Study of Abiraterone Acetate (JNJ-212082) and Docetaxel in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Cohort 4; Cohort 3; Cohort 2; Cohort 1

Prostate Cancer, Hormone-resistant Prostate Cancer, Recurrent Pro Clinical Trial using laboratory biomarker analysis; questionnaire administration; doxorubicin-GnRH agonist conjugate AEZS-108

University of Southern California - Recruiting 18 years or older.
- A Phase I/II Trial of AN-152 [AEZS-108) in Castration- and Taxane-Resistant Prostate Cancer.
laboratory biomarker analysis; questionnaire administration; doxorubicin-GnRH agonist conjugate AEZS-108

Metastatic Prostate Cancer Clinical Trial using cabacitaxel

Tampere University Hospital - Recruiting 18 years or older.
- Open, Single-arm, Multicenter, Phase II Trial Investigating the Safety of Biweekly Cabazitaxel in Metastatic Castration Resistant Prostate Cancer Patients Previously Treated With a Docetaxel-containing Regimen.
cabacitaxel

Diarrhea, Hormone-resistant Prostate Cancer, Recurrent Prostate C Clinical Trial using cabazitaxel; prednisone; octreotide pamoate; questionnaire administration; octreotide acetate

University of Southern California - Recruiting 18 years or older.
- A Phase II Clinical Trial of Cabazitaxel Plus Prednisone With Octreotide in the Treatment of Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel.
cabazitaxel; prednisone; octreotide pamoate; questionnaire administration; octreotide acetate

Prostate Cancer Clinical Trial using Docetaxel, Reolysin and Prednisone; Docetaxel and Prednisone

NCIC Clinical Trials Group - Recruiting 18 years or older.
- A Randomized Phase II Study of Reolysin in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Castration Resistant Prostate Cancer.
Docetaxel, Reolysin and Prednisone; Docetaxel and Prednisone

Prostate Cancer Clinical Trial using CABAZITAXEL (XRP6258); Prednisone; Ciprofloxacin; G-CSF (Granulocyte colony-stimulating factor)

Sanofi - Recruiting 18 years or older.
- A Phase IV, Multicenter, National, Non-comparative, Open-label Study of Cabazitaxel, Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Second-line Treatment of Patients With Metastatic Castration-resistant Prostate Cancer and After Failure of Docetaxel-based Chemotherapy. Descriptive Assessment of the Circulating Tumor Cells in This Context..
CABAZITAXEL (XRP6258); Prednisone; Ciprofloxacin; G-CSF (Granulocyte colony-stimulating factor)

Bone Metastases, or Castration-Resistant Prostate Cancer Clinical Trial using Alpharadinr (Radium-223 dichloride) + docetaxel; Docetaxel

Algeta ASA - Recruiting 18 years or older.
- A Phase I/IIa Study of Safety and Efficacy of Alpharadinr With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer.
Alpharadinr (Radium-223 dichloride) + docetaxel; Docetaxel

Metastatic Castration-resistant Prostate Cancer Clinical Trial using Taxotere; Jevtana

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 18 years or older.
- A Study of Patient Preference Between Cabazitaxel and Docetaxel in First-line Chemotherapy for Metastatic Castrate-resistant Prostate Cancer.
Taxotere; Jevtana

Prostatic Neoplasms Clinical Trial using CFG920

Novartis - Recruiting 18 years or older.
- A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer.
CFG920

Prostate Cancer Clinical Trial using Orteronel; Bicalutamide

European Organisation for Research and Treatment of Cancer - EORTC - Recruiting 18 years or older.
- Phase II Randomized Comparative Trial of TAK-700 (Orteronel) Versus Bicalutamide in Metastatic Prostate Cancer Patients Failing 1st Line Treatment With LHRH Agonists or Surgical Castration..
Orteronel; Bicalutamide

Castration-Resistant Prostate Cancer Clinical Trial

Dendreon - Recruiting 18 years or older.
- A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer.

Prostate Cancer Clinical Trial using PET/CT; PET/MRI

New York University School of Medicine - Recruiting 18 years or older.
- Multimodality Imaging Assessment of Sipuleucel T Treatment and in Vivo Immune Response of Metastatic Castration Resistant Prostate Cancer Patients.
PET/CT; PET/MRI

Prostate Cancer Clinical Trial using Enzalutamide; Abiraterone; Placebo for Enzalutamide; Prednisone

Medivation, Inc. - Recruiting 18 years or older.
- A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study of Continued Enzalutamide Treatment Beyond Progression in Patients With Chemotherapy-Na‹ve Metastatic Castration-Resistant Prostate Cancer.
Enzalutamide; Abiraterone; Placebo for Enzalutamide; Prednisone

Prostate Cancer Clinical Trial using Cancer Macrobead placement in abdominal cavity

The Rogosin Institute - Recruiting 18 years or older.
- An Open-Label, Phase 2 Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Cell-Containing Agarose- Agarose Macrobeads in the Treatment of Patients With Castration-Resistant Prostate Cancer Resistant to Docetaxel.
Cancer Macrobead placement in abdominal cavity

Prostate Cancer Clinical Trial using Cabozantinib; Abiraterone

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Dose Finding Clinical Trial of Cabozantinib (XL 184) Administered in Combination With Abiraterone in Castration Resistant Prostate Cancer.
Cabozantinib; Abiraterone

Prostate Cancer, Castration Resistant Prostate Cancer, or Prostat Clinical Trial using cabozantinib; abiraterone; prednisone

Exelixis - Recruiting 18 years or older.
- A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination With Abiraterone in Chemotherapy Na‹ve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer.
cabozantinib; abiraterone; prednisone

Prostate Cancer Clinical Trial using Abiraterone; Prednisone

Massachusetts General Hospital - Recruiting 18 years or older.
- Investigator-Initiated, Pilot Translational Study of Circulating Tumor Cells to Identify Predictive Factors of Response to Abiraterone Acetate in Men With Castration-Resistant Prostate Cancer.
Abiraterone; Prednisone

Castration Resistant Prostate Cancer Clinical Trial using SOM230

Novartis - Recruiting 18 years or older.
- Phase 1 Study to Evaluate Safety, and Preliminary Efficacy of Pasireotide LAR in Castration Resistant Prostate Cancer.
SOM230

Nonmetastatic Castration-Resistant Prostate Cancer Clinical Trial using Enzalutamide; Placebo

Medivation, Inc. - Recruiting 18 years or older.
- A Multinational, Phase 3, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer.
Enzalutamide; Placebo

Pharmacogenetic Study Clinical Trial using Abiraterone Acetate

Centre Antoine Lacassagne - Recruiting 18 years to 90 years.
- Pharmacogenetic Study in Castration-resistant Prostate Cancer Patients Treated With Abiraterone Acetate.
Abiraterone Acetate

Metastatic Castration- Resistant Prostate Cancer (mCRCP) Clinical Trial using Enzalutamide

Astellas Pharma Inc - Recruiting N/A or older.
- A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure.
Enzalutamide

Metastatic Castration Resistant Prostate Cancer (CRPC) Clinical Trial using Hamsa-1T TL-118

Tiltan Pharma Ltd. - Recruiting 18 years or older.
- A Phase IIB Clinical Trial of the Anti-Angiogenic Drug Combination Hamsa-1T in Metastatic Castration Resistant Prostate Cancer (CRPC).
Hamsa-1T TL-118

Prostate Cancer Clinical Trial using GTx-758 125 mg; GTx-758 250 mg

GTx - Recruiting 18 years or older.
- Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy.
GTx-758 125 mg; GTx-758 250 mg

Metastatic Castration Resistant Prostate Cancer Patients Clinical Trial using metastasis biopsy

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 18 years or older.
- Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program.
metastasis biopsy

Prostate Cancer Clinical Trial using Pantoprazole

University Health Network, Toronto - Recruiting 18 years or older.
- Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer - a Single Arm Phase II Clinical Trial With a Predefined Reference Group (PANDORA).
Pantoprazole